MTX优化或加用bDMARD均等同改善类风湿关节炎疾病活动度:STRATEGE前瞻性研究结果
STRATEGE研究在722例MTX单药治疗应答不足的RA患者中描述当前治疗策略,并比较不同策略6个月后的临床疗效。识别出MTX优化(72%)和起始bDMARD±MTX(16%)两种主要策略,倾向评分校正后两者在改善疾病活动度和躯体功能方面同样成功,EULAR良好至中度应答率分别为63%和68%。
要点
- MTX应答不足的RA患者中,MTX优化与起始bDMARD在6个月时改善疾病活动度方面同样有效。
- 起始bDMARD时MTX平均剂量为17.4 mg/周,96%患者同时维持MTX治疗。
- 研究强调在起始生物制剂前优化初始MTX治疗以及达标治疗策略的重要性。
核心结论
- 在MTX单药治疗应答不足的RA患者中,MTX优化与起始bDMARD±MTX两种策略在6个月时同等成功地改善疾病活动度和躯体功能。
研究设计与样本
- STRATEGE为前瞻性、观察性、多中心研究,纳入722例确诊RA、接受MTX单药治疗且需要调整治疗管理的bDMARD初治患者。
主要发现
- 纳入患者平均RA病程5.3(6.7)年,平均DAS28为4.0(1.1),均接受MTX单药治疗,68%为口服,平均剂量15.0(4.1)mg/周。
- 识别出两种主要策略:MTX单药剂量和/或给药途径优化(72%)与起始bDMARD±MTX(16%)。
- 70%患者调整了MTX剂量,28%维持剂量和途径不变,2%中断MTX。
- 起始bDMARD时MTX平均剂量为17.4 mg/周,56%经胃肠外给药,96%患者同时维持MTX治疗。
- 6个月随访经倾向评分校正后,两种策略EULAR良好至中度应答率分别为63%和68%。
关键数值与推荐
- 主要纳入标准为确诊RA、接受MTX单药治疗且需要调整治疗管理。
- 主要结局为6个月后疾病活动度,采用EULAR应答评估。
临床怎么用
- 对MTX应答不足的RA患者,应先优化MTX剂量和/或给药途径,再考虑起始生物制剂。
- 起始bDMARD时应考虑同时维持MTX治疗,并遵循达标治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The STRATEGE (Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis) study aimed to describe treatment strategies in current practice in RA biologic DMARD (bDMARD)-naïve patients with an inadequate response to MTX therapy, and to compare clinical efficacy of the different therapeutic strategies on disease activity after 6 months. METHODS: The main inclusion criteria of this prospective, observational, multicentre study were confirmed RA diagnosis, treatment by MTX monotherapy and need for therapeutic management modification. RESULTS: The 722 patients included had a mean (s.d.) RA duration of 5.3 (6.7) years, a mean DAS28 of 4.0 (1.1); they were all receiving MTX monotherapy, 68% oral, at a mean dose of 15.0 (4.1) mg/week. Two major strategies were identified: (i) MTX monotherapy dose and/or route optimization (72%) and (ii) bDMARD initiation ± MTX (16%). MTX dosing was modified for 70% of patients, maintained (dose and route) for 28% of patients and interrupted for 2%. bDMARDs were started when the MTX mean dose was 17.4 mg/week, 56% parenterally; MTX was maintained concomitantly for 96% of patients. Six-month follow-up results adjusted by propensity score showed that both options were equally successful in improving disease activity and physical function, with 63 and 68% of good-to-moderate EULAR responses, respectively. CONCLUSION: The STRATEGE study shows the importance of initial MTX treatment optimization before initiation of a biological treatment and emphasizes the importance of treat-to-target strategy. TRIAL REGISTRATION: ClinicalTrials.gov NCT02288520.
引用
- Gaujoux-Viala C, Hudry C, Zinovieva E, et al. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE. Rheumatology (Oxford). 2021. PMID: 33774669. doi:10.1093/rheumatology/keab274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。